City of Hope and UC Berkeley Develop AI-Powered Breast Cancer Risk Assessment Tool — City of Hope

Event summary

City of Hope and UC Berkeley researchers created a microfluidic platform that assesses breast cancer risk at the cellular level by squeezing individual breast epithelial cells.
The platform uses a machine learning algorithm to identify cells showing signs of accelerated aging, quantifying an individual breast cancer risk score.
The AI platform employs simple electronics, making it affordable and scalable for large-scale use.
The study, published in Lancet’s eBioMedicine, found that breast cells have a 'mechanical age' separate from chronological age, linked to breast cancer risk.
The research was supported by the National Institutes of Health and the American Cancer Society, with funding totaling over $5 million.

The big picture

This breakthrough addresses a critical gap in breast cancer risk assessment for the 90% of women without known genetic predispositions. The platform's use of affordable, scalable technology positions it to potentially transform preventive healthcare strategies. The collaboration between City of Hope and UC Berkeley highlights the growing trend of interdisciplinary research in advancing medical innovations.

What we're watching

Commercialization Path: How City of Hope will scale and commercialize the MechanoAge platform, given its potential to disrupt current breast cancer risk assessment methods.
Regulatory Approval: The pace at which the platform will gain regulatory approval for clinical use, considering its novel approach to cancer risk assessment.
Market Adoption: Whether healthcare providers and insurers will adopt this technology, given its potential to reduce over-screening and under-screening issues.